The Curapel team understands that people want to use products containing safe, naturally-occurring ingredients backed up by science and dermatological testing. Curapel has expanded its IP portfolio to 30 granted and 4 pending patent applications, allowing continued product development across eczema, psoriasis, skin pigmentation, skin microbiome, gut-skin axis and transdermal delivery.
Curapel epitomises the successful translation of academic research to commercial products that safely meet the unmet clinical needs of people with chronic skin conditions, taking its product pipeline to market for investors, stakeholders and strategic partners.
Learn more about our naturally-occurring, patent-protected skin care products.
